A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP).

drug protocol number
BAY 63-2521 / 13605
drug sponsor
Bayer
drug study
Riociguat
drug trial site
King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh)
drug status
Completed
drug phase